Table 3.
Therapeutic mAbs used for infectious diseases
| Antibody | Type | Target | Medical uses |
|---|---|---|---|
| Bezlotoxumab | Human, mAb, IgG1 | Clostridium difficile | Clostridium difficile colitis |
| Ibalizumab | Humanized, mAb, IgG4 | CD4 | Multidrug‐resistant HIV infection |
| Oblitoxaximab | Chimeric, mAb, IgG1 | Bacillus anthracis anthrax | Anthrax (prophylaxis and treatment) |
| Palivizumab | Human, mAb, IgG1 | F protein of respiratory syncytial virus | Respiratory syncytial virus (prevention) |
| Raxibacumab | Human, mAb, IgG1 | Anthrax toxin | Anthrax (prophylaxis and treatment) |
| Rmab | Human, mAb, IgG4 | Rabies virus G glycoprotein | Post‐exposure prophylaxis of rabies |